DexTech's OsteoDex meets primary and secondary goals in Phase I/IIa multiple myeloma trial

• DexTech Medical finalized the clinical report for its Phase I/IIa OsteoDex trial in relapsed or treatment-resistant multiple myeloma in October 2026.
• The report confirmed previously disclosed positive results, with the trial meeting its primary and secondary objectives.
• No serious treatment-related adverse events occurred; all patients achieved stable disease during treatment.
• Most patients maintained stable disease following treatment completion in February 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexTech Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 202610290650BITN____UKPR__SV_20261029-BIT-1853-0) on October 29, 2026, and is solely responsible for the information contained therein.